GlassScriptPhysician profile
Matthew J King
NPI 1932101284
$3,902.04
in general payments reported to CMS, 2019-2025
34 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $707 · 2021: $562 · 2022: $543 · 2023: $619 · 2024: $380 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,005.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $312.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $305.74 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $290.58 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $282.62 | 2019-2023 | |
| Alkermes, INC. | $200.39 | 2019-2023 | Vivitrol |
| Abbott Laboratories | $147.14 | 2024 | Assurity |
| Abbvie INC. | $143.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $142.74 | 2020-2023 | Dificid, Zerbaxa, Recarbrio |
| Abiomed | $116.60 | 2024 | Impella |
| Mayne Pharma Commercial LLC | $95.88 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $83.29 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $76.06 | 2019-2020 | |
| Grifols USA, LLC | $73.03 | 2019-2023 | Xembify |
| Sanofi Pasteur INC. | $72.28 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62.63 | 2019-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $51.46 | 2023 | Korlym |
| Daiichi Sankyo INC. | $47.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.45 | 2019 | |
| Ferring Pharmaceuticals INC. | $36.62 | 2023 | Rebyota |
| Eisai INC. | $35.86 | 2020 | |
| Amarin Pharma, INC. | $32.97 | 2021 | |
| Exact Sciences Corporation | $30.02 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $25.23 | 2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $24.83 | 2019 | |
| Indivior INC. | $23.34 | 2019 | |
| Phadia US INC. | $19.44 | 2023 | Immunocap |
| Philips North America LLC | $19.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.08 | 2025 | Rexulti |
| Allergan, INC. | $18.32 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.99 | 2022 | |
| Seqirus USA INC | $16.24 | 2020 | |
| Mylan Specialty L.P. | $15.90 | 2019 | |
| Romark Laboratories, Lc | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.